OBJECTIVE: In the Ukraine the authorized National program «Reproductive health» which provides rational contraception of women.To carry out the pharmacoeconomical analysis of hormonal contraceptives and to validate economical advantages New-Ring compared to oral contraceptives in Ukraine.METHODS: a marketing analysis, a “cost-effectiveness” analysis. The marketing analysis of hormonal contraceptives has shown, that in Ukraine the import preparations submitted only. It is carried out the pharmacoeconomic analysis of hormonal combined contraceptives in different medical forms: vaginal rings (New–ring), scin plaster (Evra) and tablets for oral reception (Jaryna). Mean cost of contraceptives was calculated based on the minimal wholesale price and the limiting state margin - 35 % the April 2005. The costs for contraception within one year preparation Åvra have made 33396,12 Hryven (1 Euro - 6,35 Hryven.), the New-ring - 1014,96 Hrn., Jaryna - 784,08 Hrn. By results of an expert estimation of women compliance preparations following: Åvra – 88,7 %, New-ring – 81,0 %, Jaryna – 79,2 %. The maximum compliance of a plaster and vaginal rings caused by transdermal receipt of contraceptives provides, as against tablets, stable concentration of hormones during a month. RESULTS: The marketing analysis having shown necessity of creation of a domestic production contraceptives in Ukraine. Taking into account similar level of compliance to the Åvra and to the New-ring, it is possible to recommend the New-ring as an optimum contraceptive behind a CER. The analysis "cost-effectiveness" has shown, that contraception within one year Evra will cost to the woman in 4,3 times more expensive, and a ring the New-ring - in 1,3 times more expensive, than tablets Jaryna. CONCLUSIONS: The New-ring represents a less expensive alternative to long-term oral contraceptives.